IPSC Century Therapeutics Inc

Price (delayed)

$2.475

Market cap

$205.05M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.21

Enterprise value

$200.51M

Highlights
The quick ratio has increased by 32% year-on-year and by 23% since the previous quarter
The debt has declined by 14% year-on-year and by 5% since the previous quarter
Century Therapeutics's net income has decreased by 7% YoY but it has increased by 2.3% from the previous quarter
The EPS has increased by 3.9% since the previous quarter but it has declined by 2.8% year-on-year
Century Therapeutics's gross profit has plunged by 77% YoY and by 39% from the previous quarter
The revenue has dropped by 77% year-on-year and by 39% since the previous quarter

Key stats

What are the main financial stats of IPSC
Market
Shares outstanding
82.85M
Market cap
$205.05M
Enterprise value
$200.51M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.9
Price to sales (P/S)
112.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
146.36
Earnings
Revenue
$1.37M
EBIT
-$132.66M
EBITDA
-$118.22M
Free cash flow
-$98.66M
Per share
EPS
-$2.21
Free cash flow per share
-$1.58
Book value per share
$2.74
Revenue per share
$0.02
TBVPS
$5.59
Balance sheet
Total assets
$348.51M
Total liabilities
$170.62M
Debt
$44.25M
Equity
$177.88M
Working capital
$183.75M
Liquidity
Debt to equity
0.25
Current ratio
12.44
Quick ratio
12.08
Net debt/EBITDA
0.04
Margins
EBITDA margin
-8,628.8%
Gross margin
100%
Net margin
-9,742.4%
Operating margin
-10,640.4%
Efficiency
Return on assets
-35%
Return on equity
-64.4%
Return on invested capital
-37.7%
Return on capital employed
-39.9%
Return on sales
-9,683.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IPSC stock price

How has the Century Therapeutics stock price performed over time
Intraday
1.85%
1 week
-24.77%
1 month
-13.46%
1 year
-20.67%
YTD
-25.45%
QTD
-2.94%

Financial performance

How have Century Therapeutics's revenue and profit performed over time
Revenue
$1.37M
Gross profit
$1.37M
Operating income
-$145.77M
Net income
-$133.47M
Gross margin
100%
Net margin
-9,742.4%
Century Therapeutics's gross profit has plunged by 77% YoY and by 39% from the previous quarter
The revenue has dropped by 77% year-on-year and by 39% since the previous quarter
Century Therapeutics's operating margin has shrunk by 62% QoQ
The net margin has dropped by 59% since the previous quarter

Growth

What is Century Therapeutics's growth rate over time

Valuation

What is Century Therapeutics stock price valuation
P/E
N/A
P/B
0.9
P/S
112.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
146.36
The EPS has increased by 3.9% since the previous quarter but it has declined by 2.8% year-on-year
The equity has declined by 36% year-on-year and by 3.7% since the previous quarter
IPSC's price to book (P/B) is 11% lower than its last 4 quarters average of 1.0
The revenue has dropped by 77% year-on-year and by 39% since the previous quarter
The price to sales (P/S) is 21% higher than the last 4 quarters average of 91.7

Efficiency

How efficient is Century Therapeutics business performance
Century Therapeutics's ROE has plunged by 64% YoY and by 9% from the previous quarter
The return on sales has dropped by 61% since the previous quarter
Century Therapeutics's return on assets has decreased by 39% YoY and by 4.5% QoQ
The ROIC has contracted by 29% YoY and by 3% from the previous quarter

Dividends

What is IPSC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IPSC.

Financial health

How did Century Therapeutics financials performed over time
Century Therapeutics's total assets is 104% higher than its total liabilities
The current ratio has grown by 35% YoY and by 25% from the previous quarter
The quick ratio has increased by 32% year-on-year and by 23% since the previous quarter
The debt is 75% smaller than the equity
The equity has declined by 36% year-on-year and by 3.7% since the previous quarter
IPSC's debt to equity is up by 32% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.